Maxim Group Has Lowered Expectations for Theriva Biologics (NYSEAMERICAN:TOVX) Stock Price

Theriva Biologics (NYSEAMERICAN:TOVX) had its target price dropped by Maxim Group from $25.00 to $6.00 in a report released on Wednesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Maxim Group’s price target indicates a potential upside of 344.44% from the company’s previous close.

Theriva Biologics Stock Performance

NYSEAMERICAN TOVX opened at $1.35 on Wednesday. The firm has a market cap of $3.06 million, a price-to-earnings ratio of -0.04 and a beta of 1.34. Theriva Biologics has a 1 year low of $1.24 and a 1 year high of $17.11.

Theriva Biologics (NYSEAMERICAN:TOVX) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($6.81) earnings per share for the quarter, missing analysts’ consensus estimates of ($6.25) by ($0.56).

About Theriva Biologics

Theriva Biologics, Inc, a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company’s lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors.